I think I can look at this one an hour drive away. The title is "Ruxolitinib Withdrawal Syndrome Leading to Tumor Lysis" and Morgan Stanley is making a big deal of it. Given the starts and stops that have been observed in the reported trials, I doubt that it IS a big deal, but again, I don't have convenient access to the article, or even to an abstract. I WILL point out that tumor lysis is not, on its face, an alarming development.
The commentary from Morgan Stanley makes it clear that they think the actual market for Jakafi is much smaller than most other observers think (that it is only appropriate for sick and progressing patients).